2,3,4,5-Tetramethoxyamphetamine

TeMA
Clinical data
Other namesTeMA; TA; 2,3,4,5-TeMA; 2,3,4,5-Tetramethoxyamphetamine; 2,3,4,5-Tetramethoxyphenylisopropylamine; 2-Methoxy-TMA; 2-Methoxy-3,4,5-TMA; 3-Methoxy-TMA-2; 3-Methoxy-2,4,5-TMA
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1-(2,3,4,5-tetramethoxyphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H21NO4
Molar mass255.314 g·mol−1
3D model (JSmol)
  • CC(Cc1cc(c(c(c1OC)OC)OC)OC)N
  • InChI=1S/C13H21NO4/c1-8(14)6-9-7-10(15-2)12(17-4)13(18-5)11(9)16-3/h7-8H,6,14H2,1-5H3 checkY
  • Key:WVNJEHORYAZBRZ-UHFFFAOYSA-N checkY
  (verify)

Tetramethoxyamphetamine (TeMA), or 2,3,4,5-tetramethoxyamphetamine (2,3,4,5-TeMA), also known as 2-methoxy-TMA or 3-methoxy-TMA-2, is a drug of the phenethylamine and amphetamine families related to mescaline (3,4,5-trimethoxyphenethylamine).

In his book PiHKAL (Phenethylamines I Have Known And Loved), Alexander Shulgin lists TeMA's "probably above 50 mg" orally and its duration as unknown. In an earlier publication, it was said to produce threshold effects at a dose of 30 mg orally and long-lived effects at a dose of 50 mg orally. The effects of TeMA have been reported to include disinhibition, intoxication, pupil dilation, and headache. It is said to be roughly 6 times as potent as mescaline. TeMA has been said to be the only amphetamine with more than three methoxy groups known to be hallucinogenic. However, the psychedelic properties of TeMA were subsequently questioned.

The chemical synthesis of TeMA has been described.

TeMA was first described in the scientific literature by at least 1975. Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991. The drug is a controlled substance in Canada under phenethylamine blanket-ban language.

See also